small molecule

LANSOPRAZOLE

LANSOPRAZOLE

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanyDEXCEL PHARMA TECHNOLOGIES LTD

Drug detail

Brand nameLANSOPRAZOLE
Active ingredientLANSOPRAZOLE
Strength15MG
Dosage formTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2016
Marketing statusOTC

Listed patents

PatentExpiresType
11077055April 2036product
11986554April 2036product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LANSOPRAZOLE patent cliff — loss of exclusivity April 2036 | CliffBio